IPG7236 for Advanced Cancer
Trial Summary
What is the purpose of this trial?
This trial tests a new drug, IPG7236, in patients with advanced solid tumors to see if it is safe and can help shrink their tumors.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you have taken any investigational or FDA-approved anti-cancer drugs within 14 days or 5 half-lives before the first dose of the study drug, or if you have had recent radiotherapy, chemotherapy, or certain other treatments. It's best to discuss your specific medications with the study team.
Research Team
Eligibility Criteria
Adults with advanced solid tumors that are metastatic or unresectable, who have not responded to standard treatments or cannot tolerate them. They must be able to take oral medication and commit to the study's schedule. Women of childbearing potential and men with partners of childbearing potential must use effective contraception.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive escalating doses of IPG7236 to determine the maximum tolerated dose
Dose Expansion
Participants receive the recommended Phase 2 dose of IPG7236 to evaluate safety and anti-tumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- IPG7236 (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nanjing Immunophage Biotech Co., Ltd
Lead Sponsor